use of inactivated non-replicating modified vaccinia ankara virus (mva) as monoimmunotherapy or in combination with solid tumor immune checkpoint blocking agents

摘要

The present disclosure relates to infection-inactivated but non-replicating inactivated modified vaccinia ankara (mva) and its use as an immunotherapy, either alone or in combination with immune checkpoint blocking agents for the treatment of malignant solid tumors. Particular embodiments refer to the induction of an immune response in an individual diagnosed with a solid malignant tumor.